HC Wainwright & Co. Maintains Buy Rating and $37.00 Price Target on SpyGlass Pharma
HC Wainwright & Co. has reaffirmed its positive outlook on SpyGlass Pharma, maintaining a 'Buy' rating and a $37.00 price target for the company's shares.
Stocks · News reference
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39
Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
8-K filing — SpyGlass Pharma, Inc. (SGP)
Filed: 2026-10-19 AccNo: 0001778922-26-000052 Size: 213 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye